Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism CCR9 antagonists(C-C chemokine receptor type 9 antagonists) |
Therapeutic Areas- |
Active Indication- |
Inactive Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H19ClN2O5S |
InChIKeyYSCNTJOPTXIIJO-UHFFFAOYSA-N |
CAS Registry628300-71-0 |
Phase 1 | - | 23 | placebo+MLN3126 (Part A: Placebo) | pkxqcsvlte(gbwnglrcqu) = mzmtofcuuh dhgzvpeqeh (bygvgeiway, kxfxicloib - ocasiilrns) View more | - | 25 Jul 2016 | |
(Part A: MLN3126 100 mg) | pkxqcsvlte(gbwnglrcqu) = pedopwogjx dhgzvpeqeh (bygvgeiway, rtigsbyfon - zvfcebcwgu) View more | ||||||
Phase 1 | - | 39 | (MLN3126 300 mg) | kqzputxomt(cqejqajtlc) = cqhzrifeav jppivryzly (nxomseqhan, kwzszahbkx - phledupxns) View more | - | 05 Aug 2015 | |
(MLN3126 600 mg) | kqzputxomt(cqejqajtlc) = fixsgiezaf jppivryzly (nxomseqhan, zmuqdrflst - ilkqfhulip) View more |